Barclays
TRDA icon

Barclays’s Entrada Therapeutics TRDA Stock Holding History

Barclays’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Sell
28,600
-76
-0.3% -$729 ﹤0.01% 3660
2026
Q1 		$362K Sell
28,676
-38,471
-57% -$441K ﹤0.01% 3369
2025
Q4 		$690K Buy
67,147
+6,517
+11% +$54.9K ﹤0.01% 3673
2025
Q3 		$352K Buy
60,630
+2,548
+4% +$14.9K ﹤0.01% 4001
2025
Q2 		$390K Buy
58,082
+18,431
+46% +$148K ﹤0.01% 3897
2025
Q1 		$358K Sell
39,651
-11,714
-23% -$146K ﹤0.01% 3726
2024
Q4 		$888K Buy
51,365
+6,255
+14% +$113K ﹤0.01% 3453
2024
Q3 		$721K Buy
45,110
+30,585
+211% +$482K ﹤0.01% 3561
2024
Q2 		$207K Sell
14,525
-7,992
-35% -$114K ﹤0.01% 3557
2024
Q1 		$319K Sell
22,517
-9,213
-29% -$130K ﹤0.01% 3854
2023
Q4 		$479K Buy
31,730
+25,798
+435% +$382K ﹤0.01% 3903
2023
Q3 		$93.7K Sell
5,932
-508
-8% -$8K ﹤0.01% 3621
2023
Q2 		$97.5K Sell
6,440
-3,788
-37% -$52.2K ﹤0.01% 3575
2023
Q1 		$148K Sell
10,228
-544
-5% -$7.26K ﹤0.01% 3967
2022
Q4 		$146K Buy
10,772
+9,557
+787% +$168K ﹤0.01% 4012
2022
Q3 		$19K Buy
1,215
+1,179
+3,275% +$15K ﹤0.01% 4083
2022
Q2 		$0 Sell
36
-1,673
-98% -$12.7K ﹤0.01% 5271
2022
Q1 		$16K Buy
+1,709
New +$18.3K ﹤0.01% 4509

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Barclays's TRDA Position: Q2 2026 in Review

Barclays reduced its Entrada Therapeutics (TRDA) stake by 0.27% in Q2 2026, selling an estimated $729 and leaving 28,600 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #3660.

Barclays first reported a position in TRDA in Q1 2022 and has held it in 18 quarters since. The position peaked at $888K in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Barclays held 28,600 shares of Entrada Therapeutics worth $210K as of Q2 2026.
  • Barclays sold 76 Entrada Therapeutics shares in Q2 2026, an estimated $729.
  • Entrada Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3660 holding.
  • Barclays first reported a position in Entrada Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Entrada Therapeutics position peaked at $888K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.